No material corporate news briefings were provided for Amgen Inc. in the 30 days preceding this report's generation date of 2026-06-09. The report is principally driven by notable institutional position changes recorded in recent 13F filings, supplemented by the most recent quarterly financial data and insider transaction records [Brief - 2026-06-01] [Brief - 2026-05-24].
For the trailing twelve months ending 2026-03-31, Amgen reported revenue of $37.22 billion, representing year-over-year growth of 5.76%. Net income for the same period stood at $7.80 billion, with a net margin of 20.96% and an operating margin of 28.39%. Gross margin was recorded at 48.58%. Earnings per share grew 4.38% year-over-year. The company held $12.04 billion in cash against total debt of $59.32 billion. The price-to-earnings ratio stood at 24.06, with a market capitalisation of approximately $186.59 billion [SEC 10-Q - AMGN - 2026-03-31].
Insider activity recorded 11 transactions in the most recent 30-day window, with a mixed net direction and a net value of zero, indicating no dominant disposal or acquisition pattern among insiders [SEC Form 4 - AMGN - 2026-06]. At the institutional level, Bridgewater added 389% to its reported AMGN position, while Millennium added 47%. Conversely, AQR Capital reduced its position by 30% and Citadel reduced its position by 9.4% [SEC 13F - Bridgewater - Q1 2026] [SEC 13F - Millennium - Q1 2026] [SEC 13F - AQR Capital - Q1 2026] [SEC 13F - Citadel - Q1 2026].
The prevailing macroeconomic rate environment shows the 10-year US Treasury yield (DGS10) at 4.55% and the 2-year yield (DGS2) at 4.17%, reflecting a normal yield curve configuration with a spread of 38 basis points [FRED DGS10] [FRED DGS2]. This report was generated principally in response to the material institutional position changes described above.